Santarus, Inc. (Santarus) is a specialty pharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by gastroenterologists or primary care physicians. Santarus focuses on commercializing of its Zegerid immediate-release proton pump inhibitor (PPI) products. PPI products are used for the treatment of many upper gastrointestinal (GI) diseases and disorders, including gastroesophageal reflux disease (GERD). The Company’s Zegerid products are immediate-release formulations that combine omeprazole, a PPI, and one or more antacids.